Los Angeles Capital Management LLC Takes Position in Abeona Therapeutics Inc. $ABEO

Los Angeles Capital Management LLC bought a new position in shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 268,148 shares of the biopharmaceutical company’s stock, valued at approximately $1,523,000. Los Angeles Capital Management LLC owned approximately 0.52% of Abeona Therapeutics at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Riverwater Partners LLC acquired a new position in Abeona Therapeutics during the 2nd quarter valued at about $62,000. OMERS ADMINISTRATION Corp lifted its holdings in shares of Abeona Therapeutics by 11.0% in the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company’s stock valued at $344,000 after purchasing an additional 7,155 shares in the last quarter. Trexquant Investment LP lifted its holdings in shares of Abeona Therapeutics by 74.1% in the first quarter. Trexquant Investment LP now owns 119,274 shares of the biopharmaceutical company’s stock valued at $568,000 after purchasing an additional 50,758 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Abeona Therapeutics during the second quarter valued at approximately $581,000. Finally, Wellington Management Group LLP grew its holdings in Abeona Therapeutics by 64.1% during the first quarter. Wellington Management Group LLP now owns 153,121 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 59,832 shares in the last quarter. Institutional investors own 80.56% of the company’s stock.

Insiders Place Their Bets

In other Abeona Therapeutics news, CFO Joseph Walter Vazzano sold 9,035 shares of the business’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $48,698.65. Following the sale, the chief financial officer directly owned 453,631 shares in the company, valued at $2,445,071.09. The trade was a 1.95% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Brendan M. O’malley sold 9,366 shares of Abeona Therapeutics stock in a transaction dated Monday, September 29th. The stock was sold at an average price of $5.39, for a total value of $50,482.74. Following the completion of the sale, the senior vice president directly owned 350,763 shares of the company’s stock, valued at approximately $1,890,612.57. This trade represents a 2.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 63,612 shares of company stock valued at $339,171 over the last ninety days. 6.90% of the stock is currently owned by insiders.

Abeona Therapeutics Stock Down 1.4%

ABEO opened at $4.17 on Wednesday. The company has a quick ratio of 6.65, a current ratio of 6.73 and a debt-to-equity ratio of 0.09. The stock has a market cap of $213.83 million, a price-to-earnings ratio of 5.96 and a beta of 1.45. Abeona Therapeutics Inc. has a twelve month low of $3.93 and a twelve month high of $7.54. The company’s 50-day moving average price is $5.47 and its two-hundred day moving average price is $6.00.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $2.10. The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $21.71 million. As a group, equities analysts expect that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ABEO shares. Oppenheimer lifted their price objective on shares of Abeona Therapeutics from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Friday, August 15th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Monday, October 13th. Finally, Weiss Ratings cut shares of Abeona Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, October 24th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.